date:Jan 21, 2019
imal. That being said, I remain rather pessimistic regarding seeing material improvements in the near term, he notes.
In a recent interview, Chr. Hansen CEO, Mauricio Graber, noted organic growth through innovation and regional expansion as central to the companys continued advance. The companys Cultures Enzymes business, which features more than 30,000 microbial strains, is particularly thriving amid new market dynamics.
Chr. Hansen built a very good business through their knowledge of lact